BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• 

  Opinion

  Drugs Are Becoming ‘Smarter.’ Here’s How

  Digitization enables each drug to have a software-enhanced version optimized for individual patients.

  November 11, 2024

   · 

  6 min read

   · 

  David Benshoof Klein
• 

  Policy

  GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future

  GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug price negotiation program.

  November 11, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Huntington’s

  After Decades of Failure, First Disease-Modifying Huntington’s Treatment on the Horizon

  The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies including Prilenia and Wave Life Sciences eye paths to approval of therapies that could address the underlying cause of the disease.

  November 11, 2024

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Schizophrenia

  AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials

  The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.

  November 11, 2024

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  FDA

  UPDATE: FDA Lifts Clinical Hold on Novavax’s COVID/Flu Vaccine Candidates, Clears Phase III Trial

  Novavax’s shared jumped 12% in pre-market trading on the news.
  

  November 11, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Huntington’s

  5 Huntington’s Therapies to Watch

  A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win. Here, BioSpace looks at five candidates that could change the trajectory for patients.

  November 11, 2024

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Alzheimer’s

  Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024

  With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s Disease conference focused on the role these drugs might play, as well as combination therapies and innovative new treatment options.

  November 11, 2024

   · 

  6 min read

   · 

  Kate Goodwin
• 

  Immunology and inflammation

  AstraZeneca, Amgen Claim Late-Stage Win in Chronic Rhinosinusitis but Analyst Flags ‘Regulatory Risk’

  The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not expect the antibody to outperform Dupixent.

  November 11, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pipeline

  RAPT Crashes After Axing Atopic Dermatitis, Asthma Hopeful, Cites Liver Injury

  In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

  November 11, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Conflixis Raises $4.2 Million in Seed Funding to Transform Conflicts of Interest (COI) Management in Healthcare

  November 11, 2024

   · 

  3 min read